Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: marek k. Nat Med. 2024 Apr;30(4):1096-1103. doi: 10.1038/s41591-024-02886-y. Epub 2024 Apr 15. Nat Med. 2024. PMID: 38622249 Free PMC article.
Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.
Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, Simuni T, Postuma RB, Pavese N, Stocchi F, Brockmann K, Smigorski K, Gerbaldo V, Fontoura P, Doody R, Kerchner GA, Brundin P, Marek K, Bonni A, Nikolcheva T; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: marek k. Nat Med. 2024 Oct 8. doi: 10.1038/s41591-024-03270-6. Online ahead of print. Nat Med. 2024. PMID: 39379705
Eleven Years of Change: Disease Progression in Biomarker-Defined Sporadic Parkinson's Disease.
Gonzalez-Latapi P, Gochanour C, Cho H, Ho Choi S, Caspell-Garcia C, Coffey C, Brumm M, Lafontant DE, Xiao Y, Tanner C, Venuto CS, Kieburtz K, Chahine LM, Poston KL, Siderowf A, Marek K, Simuni T. Gonzalez-Latapi P, et al. Among authors: marek k. medRxiv [Preprint]. 2024 Oct 10:2024.10.09.24315191. doi: 10.1101/2024.10.09.24315191. medRxiv. 2024. PMID: 39417131 Free PMC article. Preprint.
A longitudinal program for biomarker development in Parkinson's disease: a feasibility study.
Ravina B, Tanner C, Dieuliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kieburtz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators. Ravina B, et al. Among authors: marek k. Mov Disord. 2009 Oct 30;24(14):2081-90. doi: 10.1002/mds.22690. Mov Disord. 2009. PMID: 19691116
GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
Ojo OO, Bandres-Ciga S, Makarious MB, Crea PW, Hernandez DG, Houlden H, Rizig M, Singleton AB, Noyce AJ, Nalls MA, Blauwendraat C, Okubadejo NU; Nigeria Parkinson's Disease Research Network and the Global Parkinson's Genetics Program (GP2). Ojo OO, et al. Mov Disord. 2024 Apr;39(4):728-733. doi: 10.1002/mds.29753. Epub 2024 Feb 23. Mov Disord. 2024. PMID: 38390630
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Dam T, Pagano G, Brumm MC, Gochanour C, Poston KL, Weintraub D, Chahine LM, Coffey C, Tanner CM, Kopil CM, Xiao Y, Chowdhury S, Concha-Marambio L, DiBiaso P, Foroud T, Frasier M, Jennings D, Kieburtz K, Merchant K, Mollenhauer B, Montine TJ, Nudelman K, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tolosa E, Siderowf A, Dunn B, Simuni T, Marek K; Parkinson’s Progression Markers Initiative. Dam T, et al. Among authors: marek k. NPJ Parkinsons Dis. 2024 Sep 27;10(1):178. doi: 10.1038/s41531-024-00789-w. NPJ Parkinsons Dis. 2024. PMID: 39333167 Free PMC article.
452 results